You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel Screen Approach to Inactivate Whole Viral Vaccines by Supralethal Irradiation

    SBC: AGAVE BIOSYSTEMS INC.            Topic: DTRA14B002

    Future vaccine development should focus on rapid upscale production, long-term and broad protection, and sufficient global distribution to prevent and reduce the impact of many infectious diseases and potential epidemics. Agave BioSystems proposes to develop a novel whole-microorganism vaccine inactivation strategy involving high-throughput screen of extensive radio-protectant matrices and radiati ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  2. Automated Assessment of Leptomeningeal Collaterals on CT Angiograms

    SBC: Kitware, Inc.            Topic: 108

    DESCRIPTION provided by applicant The primary goal of this study is to develop an automated scoring system of leptomeningeal collaterals based on CT angiography CTA as a quantitative assessment of acute stroke Leptomeningeal collaterals provide an alternate path of blood flow in the setting of a proximal occlusion The presence and effectiveness of leptomeningeal collaterals i e andquot c ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Prostate Cancer Assessment Via Integrated 3D ARFI Elasticity Imaging and Multi-Parametric MRI

    SBC: Kitware, Inc.            Topic: 102

    DESCRIPTION provided by applicant Prostate cancer PCA is the most common non skin cancer and the second leading cause of cancer death in American men with over new cases diagnosed and over PCA deaths annually in the United States Ultrasound guided biopsy is the standard of care for confirming cancer typically following elevated PSA levels however it has been estimated that ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    DESCRIPTION provided by applicant The treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutions Left untreated these lesions tend to degenerate to chronic pain and osteoarthritis OA ultimately requiring a total joint replacement For patients suffering from knee OA and in particular unicompartmental OA unicondylar knee arthroplasty UK ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a high-throughput assay for measuring m6A demethylase activity

    SBC: Base5 Biosciences Inc            Topic: NIDA

    DESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Synthetic lubricin biomaterial for osteoarthritis

    SBC: ARTICULATE BIOMEDICAL, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Osteoarthritis OA is a significant contributor to human morbidity and mortality with an economic burden exceeding $ billion annually in the United States Lubricin is a natural lubricant of the articular cartilage of the knee and the intraarticular administration of lubricin prevents OA progression following knee injury However the manufacture of lubrici ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. The Development of a High-Throughput Assay to Screen Chemical Compounds in Human Pluripotent Stem Cell Derived Neural Cells

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: 113

    DESCRIPTION provided by applicant The long term objective of this application is to provide a high throughput platform to test the effects of chemical exposure on human brain development In the US chemicals are not required for health or environmental safety testing before their incorporation in consumer products Over registered chemicals are in commerce most of which are used withou ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Mass Spectrometric Screening of the Effect of Chemical Toxicants on the Human Epitranscriptome during Stem Cell Differentiation

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: 113

    DESCRIPTION provided by applicant Epitranscriptomics explores levels and evolution of RNA modifications as a response from intra and inter cellular stimuli These modifications and the levels at which they are present are emerging as important regulators of biological processes Perturbations such as chemical toxicants exposure can alter the patterns of specific modifications on RNA sub types ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government